A Phase I/II Study of CP-4055 in Patients With Platinum Resistant Ovarian Cancer

Inclusion Criteria: * Histologically or cytologically documented advanced epithelial ovarian cancer measurable with CT and/or MRI * Received prior chemotherapy regimen(s) for ovarian cancer, at least one being a platinum based therapy (PBT) * Evidence of platinum resistant or refractory disease * ECOG Performance Status 0 - 1 * Life expectancy \> 3 months * Signed informed consent (IC) * Women of child-bearing potential must have a negative serum or urine pregnancy test. Nursing patients are excluded. * Women of child-bearing potential must not become pregnant while participating in the study * Adequate haematological and biological functions Exclusion Criteria: * Patients with mixed mullerian tumours (MMT) (carcinosarcomas) * Known brain metastases * Another known active cancer within the last 5 years * Radiotherapy to more than 30 % of bone marrow * Participation in another therapeutic clinical study within 30 days of enrolment or during this clinical study * Concomitant treatment with a non-permitted medication * A history of allergic reactions or sensitivity attributed to compounds of similar or biological composition to CP-4055, i.e., ara-C and/or egg * Any serious concomitant systemic disorders incompatible with the clinical study * Any significant CNS or psychiatric disorder(s) that would hamper the patient's compliance * Pregnancy or breastfeeding * Known positive status for HIV and/or hepatitis B or C * Drug and/or alcohol abuse * Any reason why, in the investigator's opinion, the patient should not participate